Anti-Inflammatory Therapeutics Market to 2017 - Respiratory Diseases and Arthritis Continue to Dominate

Anti-Inflammatory Therapeutics Market to 2017 - Respiratory Diseases and Arthritis Continue to Dominate

Summary

GBI Research, the leading business intelligence provider, has released its latest research, “Anti-Inflammatory Therapeutics Market to 2017 - Respiratory Diseases and Arthritis Continue to Dominate”, which provides insights into anti-inflammatory therapeutics revenue forecasts until 2017. The report also examines the global anti-inflammatory treatment usage patterns. In addition, the geographical distribution of anti-inflammatory therapies across the US, the top five countries in Europe, and Japan is also provided in the report. The report also includes insights into the anti-inflammatory R&D pipeline. The report provides an in-depth analysis of the top seven inflammatory therapeutic indications, which are respiratory diseases, arthritis, multiple sclerosis, psoriasis, spondyloarthropathies, inflammatory bowel disease and gout. Furthermore, it also includes the market forecasts and treatment usage patterns of these seven therapeutic indications. The report also explores the competitive landscape, including top companies benchmarking. Finally, the key trend analysis on Mergers and Acquisitions (M&As) and licensing agreements involving anti-inflammatory treatments is also presented.

The in-depth analysis of the report is based on proprietary databases, primary and secondary research, and in-house analysis by the GBI Research team of experts.

GBI Research analysis showed that the global inflammatory therapeutics market was estimated at $57.8 billion in 2010, representing a cumulative annual growth rate of 7.6% between 2002 and 2010. GBI Research forecasts that the market will grow at a Compound Annual Growth Rate (CAGR) of 5.8% between 2010 and 2017, to record a sales value of $85.9 billion. The patent expiry of some major drugs by 2017 is expected to make way for the entry of generics, whereas this impact will be reversed by a number of strong pipeline molecules.

GBI Research has segmented each section of the anti-inflammatory therapeutics market into branded and generics, and estimates the global inflammatory therapeutics to gain 73.1% of revenue from the branded market, whereas 26.9% was achieved from the generics market in 2010. Due to the presence of a strong pipeline portfolio for anti-inflammatories, the branded share is forecast to increase to 78.6% in 2017, and the generics market will decrease to 21.4%.

GBI Research analysis shows that the R&D pipeline for anti-inflammatory therapeutics is strong. Many of the major pharmaceutical companies such as Abbott, Amgen Inc., Johnson & Johnson, GlaxoSmithKline, AstraZeneca, Merck, Pfizer, Eli Lilly, Boehringer Ingelheim and Sanofi are either entering or expanding into the market. They are collaborating with or acquiring small and medium-sized enterprise (SME) pharmaceuticals, which have promising anti-inflammatory drugs in their pipeline. Currently, more than 1,000 molecules are in R&D, with 12% of them in Phase III, 36% in Phase II, 15% in Phase I, 29% in preclinical stage, and 7% in discovery phase. This indicates that anti-inflammatory R&D will be very active for at least the next seven to eight years. The main factor that is driving the big pharmaceutical companies towards the inflammatory therapeutics market is the large patient base. Respiratory diseases and arthritis continue to be some of the most common diseases and are among the leading causes behind major chronic disabilities in the workforce.

Scope

- Data and analysis on the inflammatory therapeutics market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.
- Annualized market data for the inflammatory therapeutics market from 2002 to 2010, with forecasts to 2017.
- Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
- Analysis of the leading therapeutic segments, including respiratory diseases, arthritis, multiple sclerosis, psoriasis, spondyloarthropathies, inflammatory bowel disease and gout.
- Key drivers and restraints that have a significant impact on the market.
- The competitive landscape of the global inflammatory therapeutics market, including top companies benchmarking. The key companies studied in this report are Abbott, Amgen Inc., Johnson & Johnson, GlaxoSmithKline, AstraZeneca, Merck, Pfizer, Eli Lilly, Boehringer Ingelheim and Sanofi.
- Key M&A activities and Licensing Agreements that took place in 2004 and 2010 in the inflammatory therapeutics market.

Reasons to buy

- Build effective strategies to launch their pipeline products by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious. SHOW LESS READ MORE >

1
1 3
1.1 List of Tables 7
1.2 List of Figures 10
2 Anti-Inflammatory Therapeutics Market to 2017: Introduction 12
2.1 GBI Research Report Guidance 13
3 Anti-Inflammatory Therapeutics Market to 2017: Market Overview 14
3.1 Introduction 14
3.1.1 Revenue 14
3.1.2 Branded Vs Generics 15
3.1.3 Annual Cost of Treatment 16
3.1.4 Treatment Usage Pattern 17
4 Anti-Inflammatory Therapeutics Market to 2017: Geographical Landscape 19
4.1 Revenue Analysis by Geography 19
4.2 The US 21
4.2.1 Revenue 21
4.2.2 Annual Cost of Treatment 22
4.2.3 Treatment Usage Patterns 23
4.3 Top Five Countries of Europe 25
4.3.1 Revenue 25
4.3.2 Annual Cost of Treatment 28
4.3.3 Treatment Usage Patterns 30
4.4 Japan 32
4.4.1 Revenue 32
4.4.2 Annual Cost of Treatment 33
4.4.3 Treatment Usage Patterns 34
5 Anti-Inflammatory Therapeutics Market to 2017: Therapeutic Landscape 36
5.1 Respiratory Diseases 36
5.1.1 Introduction 36
5.1.2 Revenue 36
5.1.3 Annual Cost of Treatment 40
5.1.4 Treatment Usage Pattern 41
5.2 Drivers and Barriers the Respiratory Therapeutics Market 43
5.2.1 Drivers for Respiratory Therapeutics Market 43
5.2.2 Barriers for Respiratory Therapeutics Market 44
5.3 Arthritis Therapeutics Market 45
5.3.1 Introduction 45
5.3.2 Revenue 45
5.3.3 Annual Cost of Treatment 48
5.3.4 Treatment Usage Pattern 49
5.4 Drivers and Barriers for Arthritis Therapeutics Market 51
5.4.1 Drivers for Arthritis Therapeutics Market 51
5.4.2 Barriers for Arthritis Therapeutics Market 52
5.5 Multiple Sclerosis Therapeutics 53
5.5.1 Introduction 53
5.5.2 Revenue 55
5.5.3 Annual Cost of Treatment 58
5.5.4 Treatment Usage Pattern 59
5.6 Drivers and Barriers for Multiple Sclerosis Therapeutics Market 61
5.6.1 Drivers for Multiple Sclerosis Therapeutics Market 61
5.6.2 Barriers for Multiple Sclerosis Therapeutics Market 62
5.7 Psoriasis Therapeutics Market 63
5.7.1 Introduction 63
5.7.2 Revenue 64
5.7.3 Annual Cost of Treatment 67
5.7.4 Treatment Usage Pattern 68
5.8 Drivers and Barriers for Psoriasis Therapeutics Market 70
5.8.1 Drivers for Psoriasis Therapeutics Market 70
5.8.2 Barriers for Psoriasis Therapeutics Market 71
5.9 Spondyloarthropathies Therapeutics Market 71
5.9.1 Introduction 71
5.9.2 Revenue 72
5.9.3 Treatment Usage Pattern 76
5.10 Drivers and Barriers for Spondyloarthropathies Therapeutics Market 78
5.10.1 Drivers for Spondyloarthropathies Therapeutics Market 78
5.10.2 Barriers for Spondyloarthropathies Therapeutics Market 79
5.11 Inflammatory Bowel Disease 79
5.11.1 Introduction 79
5.11.2 Revenue 81
5.11.3 Annual Cost of Treatment 84
5.11.4 Treatment Usage Pattern 85
5.12 Drivers and Barriers for IBD Therapeutics Market 87
5.12.1 Drivers the IBD Therapeutics Market 87
5.12.2 Barriers for IBD Therapeutics Market 88
5.13 Gout Therapeutics Market 88
5.13.1 Introduction 88
5.13.2 Revenue 91
5.13.3 Annual Cost of Treatment (ACT) 94
5.13.4 Treatment Usage Pattern 95
5.14 Drivers and Barriers for Gout Therapeutics Market 97
5.14.1 Drivers for Gout Therapeutics Market 98
5.14.2 Barriers for Gout Therapeutics Market 98
6 Anti-Inflammatory Therapeutics Market to 2017: Pipeline Analysis 99
6.1 Introduction 99
6.2 Anti-Inflammatory Therapeutics Market to 2017 – Pipeline Assessment by Clinical Phase of Development 101
6.2.1 Filed Molecules 101
6.2.2 Phase III 102
6.2.3 Phase II 111
6.2.4 Phase I 136
6.2.5 Preclinical Phase 145
6.2.6 Discovery Phase 173
6.3 Anti-Inflammatory Therapeutics Market to 2017 – Profiles of Promising Molecules 178
6.3.1 Indacaterol 178
6.3.2 BTR-15K 179
6.3.3 Flutiform 180
6.3.4 Iguratimod 181
6.3.5 OHR/AVR118 182
6.3.6 Simponi 183
6.3.7 Zushima 184
6.3.8 Civanex 184
6.3.9 Naproxcinod 185
6.3.10 Gilenia 187
6.3.11 Cladribine 187
6.3.12 Fampyra 189
6.3.13 LAS41002 189
6.3.14 BTR-15K 190
6.3.15 XOMA 052 191
7 Anti-Inflammatory Therapeutics Market to 2017: Competitive Profiling 193
7.1 Abbott Laboratories 193
7.1.1 Company Overview 193
7.1.2 Marketed Products 193
7.1.3 SWOT Analysis 193
7.2 Amgen Inc. 194
7.2.1 Company Overview 194
7.2.2 Marketed Products 194
7.2.3 SWOT Analysis 194
7.3 Johnson & Johnson 195
7.3.1 Company Overview 195
7.3.2 Marketed Products 195
7.3.3 SWOT Analysis 195
7.4 GlaxoSmithKline 196
7.4.1 Company Overview 196
7.4.2 Marketed Products 196
7.5 AstraZeneca 197
7.5.1 Company Overview 197
7.5.2 Marketed Products 197
7.5.3 SWOT Analysis 198
7.6 Merck 199
7.6.1 Company Overview 199
7.6.2 Marketed Products 199
7.6.3 SWOT Analysis 200
7.7 Pfizer 200
7.7.1 Company Overview 200
7.7.2 Marketed Products 200
7.7.3 SWOT Analysis 201
7.8 Boehringer Ingelheim GmbH 201
7.8.1 Company Overview 201
7.8.2 Marketed Products 201
7.8.3 SWOT Analysis 202
7.9 Sanofi 202
7.9.1 Company Overview 202
7.9.2 Marketed Products 202
7.9.3 SWOT Analysis 203
8 Anti-Inflammatory Therapeutics Market to 2017: Strategic Consolidations 204
8.1 M&A Deals 205
8.1.1 Deals by Year 205
8.1.2 Deals by Geography 206
8.1.3 Deals by Value ($) 207
8.1.4 Merck & Co Completes Merger with Schering-Plough 207
8.1.5 Pfizer Completes Acquisition of Wyeth 207
8.1.6 Bayer Acquires Schering 208
8.2 Licensing Agreements 208
8.2.1 Deals by Year 208
8.2.2 Deals by Geography 209
8.2.3 Deals by Value ($) 210
8.2.4 Incyte Enters Into Licensing Agreement with Pfizer 210
8.2.5 Orexo Enters Into Licensing Agreement with Ortho-McNeil-Janssen and Janssen Pharmaceutica 211
8.2.6 Cytos Biotechnology Plans to Enter Into Licensing Agreement for CYT003-QbG10 211
8.3 Co-Developments 212
8.3.1 Deals by Year 212
8.3.2 Deals by Geography 213
8.3.3 Deals by Value ($) 214
8.3.4 Galapagos Enters Into Strategic Alliance with Roche Holding 214
8.3.5 Sepracor Enters Into Co-Development Agreement with Nycomed 215
8.3.6 Galapagos Extends its Co-Development Agreement with GlaxoSmithKline 215
8.3.7 Lycera Enters Into Research Agreement with Merck 215
9 Anti-Inflammatory Therapeutics Market to 2017: Appendix 216
9.1 Market Definitions 216
9.2 Abbreviations 216
9.3 Research Methodology 217
9.3.1 Coverage 217
9.3.2 Secondary Research 218
9.3.3 Primary Research 218
9.3.4 Therapeutic Landscape 219
9.3.5 Market Size by Geography 220
9.3.6 Geographical Landscape 222
9.3.7 Pipeline Analysis 222
9.3.8 Competitive Landscape 222
9.3.9 Expert Panel Validation 222
9.4 Contact Us 222
9.5 Disclaimer 222
9.6 Sources 223

GBI Research, the leading business intelligence provider, has released its latest research, “Anti-Inflammatory Therapeutics Market to 2017 - Respiratory Diseases and Arthritis Continue to Dominate”, which provides insights into anti-inflammatory therapeutics sales and price forecasts until 2017. The report also examines the global anti-inflammatory treatment usage patterns. In addition, the geographical distribution of anti-inflammatory therapies across the US, the top five countries in the European region, and Japan is also provided in the report. The report also includes insights into the anti-inflammatory R&D pipeline. The report provides an in-depth analysis of the top seven inflammatory therapeutic indications, which are respiratory diseases, arthritis, multiple sclerosis, psoriasis, spondyloarthropathies, inflammatory bowel disease and gout. Furthermore, it also includes the market forecasts and treatment usage patterns of these seven therapeutic indications. The report also explores the competitive landscape, including top companies benchmarking. Finally, the key trend analysis on Mergers and Acquisitions (M&As) and licensing agreements involving anti-inflammatory treatments is also presented.

It is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research’s team of industry experts.

The Anti-Inflammatory Therapeutics Market is Becoming Attractive due to its Continuous Growth

Anti-Inflammatory Therapeutics Market, Global, Revenue ($bn), 2002-2017

Source: GBI Research, DrugBank, Company Annual Reports, The US Patent and Trademark Office, RxUSA

The anti-inflammatory therapeutics market accounted for $32.3 billion in 2002 from its seven major indications. From 2002, the market grew at a rate of 7.6% to $57.8 billion in 2010, and is forecast to grow at a rate of 5.8% during the forecast period, to produce revenues of $85.9 billion in 2017. This decrease from 7.6% to 5.8% will be due to patent expiries of some biologics and small molecules; these patent expiries will make an entry point for generics in the market, and their negative impact will be reversed by strong pipeline molecules that are currently in various phases of clinical trials.

The Anti-Inflammatory Therapeutics Market is one of the Major Parts of the Global Pharmaceutical Industry

The global anti-inflammatory therapeutics market in 2010 accounted for $65.8 billion, and had a growing trend which will continue during the forecast period. The anti-inflammatory therapeutics market is linked to seven diseases as major indications, which include respiratory inflammatory diseases (asthma and chronic obstructive pulmonary disease), arthritis (rheumatoid arthritis and osteoarthritis), multiple sclerosis, psoriasis, inflammatory bowel disease (Crohn’s disease and ulcerative colitis), spondyloarthropathies (ankylosing spondylitis and psoriatic arthritis), gout, and others (which includes the anti-inflammatory therapeutics market other than the seven major indications). The anti-inflammatory therapeutics market accounts for a share of 7.4% from global pharmaceutical revenues, and is expected to grow during the forecast period of seven years.

Abbott Laboratories
Amgen Inc.
Johnson & Johnson
GlaxoSmithKline
AstraZeneca
Merck
Pfizer
Boehringer Ingelheim GmbH
Sanofi